Monitoring direct thrombin inhibitors with a plasma diluted thrombin time

Thrombosis and Haemostasis

Volumn 98, Issue 1, 2007, Pages 234-243

  Love, Jason E ^a   Ferrell, Chris ^a   Chandler, Wayne L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Direct thrombin inhibitors; Lupus inhibitors; Therapeutic drug monitoring

Indexed keywords

ARGATROBAN; D DIMER; FIBRINOGEN; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR; VITAMIN K GROUP;

ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG MONITORING; FIBRINOGEN BLOOD LEVEL; HEMODILUTION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; SENSITIVITY AND SPECIFICITY; THROMBIN TIME; VITAMIN K DEFICIENCY;

ANTITHROMBINS; DRUG MONITORING; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LUPUS COAGULATION INHIBITOR; MODELS, BIOLOGICAL; PARTIAL THROMBOPLASTIN TIME; THROMBIN; THROMBIN TIME; VITAMIN K;

EID: 34447503698     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-10-0607     Document Type: Article

References (16)

1. Nutescu ED, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004; 38: 99-109.
2. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004; 164: 66-70.
3. Dang CH, Durkalski VL, Nappi JM. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2006; 26: 461-468.
4. Francis JL, Hursting JM. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis 2005; 16: 251 257.
5. Fenyvesi T, Jorg, I, Harenberg J. Monitoring of anti-coagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28: 361-368.
6. de Denus S, Spinler S. Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time. Pharmacotherapy 2002; 22: 433-435.
7. Pendelton R, Wheeler M, Rodgers G. Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome. Ann Pharmacother 2006; 40: 972-976.
8. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003-2004; 173-183.
9. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004; 17: 105-125.
10. Reid TJ, Alving BM. A quantitative thrombin time for determining levels of hirudin and hirulog. Thromb Haemost 1993; 70: 608-616.
11. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353: 1028-1040.
12. Ahmad S, Ahsan A, Hoppensteadt DA. Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. Int Angiol 1999; 18: 198-206.
13. Harenberg J, Jorg I, Fenyvesi T, et al. Treatment of patients with a history of heparin-induced thrombocy-topenia and anti-lepirudin antibodies with argatroban. J Thromb Thrombolysis 2005; 19: 65-69.
14. Gosselin RC, King JH, Janatpour KA, et al. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004; 38: 1383-1388.
15. Leo A, Winteroll S. Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring alternative anticoagulants. Clin Diagn Lab Immunol 2003; 10: 731-740.
16. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996; 10: 197-202.